SF3B1 and myeloproliferative disorder: SF3B1 mutations are disease-defining in MDS/MPN with RS and thrombocytosis (MDS/MPN-RS-T) and are seen in about 5% of chronic myelomonocytic leukemia (CMML), without a well-established association with leukemic transformation and overall survival [17].